Conclusions: Taken together, these findings demonstrate that Lyc.HCL can effectively suppress ESCC both in vitro and in vivo by targeting TRIM22 and regulating the JAK2/STAT3 and Erk pathways. Here, TRIM22 is linked to esophageal squamous cell carcinoma.